Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2016 · 10-Q
Revenue$44.19M$44.19M+53.8% vs Q1 2015 Net Income$4.83M$4.83M+553.8% vs Q1 2015 EPS Diluted$0.08$0.08+300.0% vs Q1 2015 Operating Income$6,437,000+59.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,421,000N/M Margins · derivedOperating margin14.6%+0.5 pt vs Q1 2015
Net margin10.9%+8.3 pt vs Q1 2015
ended Mar 31, 2016 · filed May 10, 2016 · 40 d after period end